The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Open accessAbstract
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · cited 1×
“One is CD26 [3] and the other is ACE-2 (angiotensinconverting enzyme 2) [4].”
BackgroundMitonuclear protein imbalance as a conserved longevity mechanism
Houtkooper, R. H., Mouchiroud, L., Ryu, D., Moullan, N., Katsyuba, E., Knott, G., Williams, R. W., & Auwerx, J. (2013) · Nature · doi:10.1038/nature12188 · Cited by 1,035
Kurz, D. J., Decary, S., Hong, Y., & Erusalimsky, J. D. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.20.3613 · Cited by 899
Zika virus cell tropism in the developing human brain and inhibition by azithromycin
Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., Mancia Leon, W. R., Krencik, R., Ullian, E. M., Spatazza, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618029113 · Cited by 506
Rapamycin decelerates cellular senescence
Demidenko, Z. N., Zubova, S. G., Bukreeva, E. I., Pospelov, V. A., Pospelova, T. V., & Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8606 · Cited by 391
Identification of senescent cell surface targetable protein DPP4
Kim, K. M., Noh, J. H., Bodogai, M., Martindale, J. L., Yang, X., Indig, F. E., Basu, S. K., Ohnuma, K., Morimoto, C., Johnson, P. F., et al. (2017) · Genes & Development · doi:10.1101/gad.302570.117 · Cited by 270 · cited 1×
“Remarkably, CD26 is known to be a bonafide cell surface marker of senescent cells [7].”
BackgroundOzsvari, B., Nuttall, J. R., Sotgia, F., & Lisanti, M. P. (2018) · Aging · doi:10.18632/aging.101633 · Cited by 138
Self-citationDasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice
Cavalcante, M. B., Saccon, T. D., Nunes, A. D. C., Kirkland, J. L., Tchkonia, T., Schneider, A., & Masternak, M. M. (2020) · Aging · doi:10.18632/aging.102772 · Cited by 80
Cited by
Nadim, M. K., Forni, L. G., Mehta, R. L., Connor, M. J., Liu, K. D., Ostermann, M., Rimmelé, T., Zarbock, A., Bell, S., Bihorac, A., et al. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00356-5 · Cited by 690
Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
da Silveira, M. P., da Silva Fagundes, K. K., Bizuti, M. R., Starck, É., Rossi, R. C., & de Resende e Silva, D. T. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00650-3 · Cited by 475
IL-6: Relevance for immunopathology of SARS-CoV-2
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.009 · Cited by 343
Metadata
- Authors
- Sargiacomo, C., Sotgia, F., & Lisanti, M. P.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2020-03-30
- Volume
- 12
- Issue
- 8
- Pages
- 6511-6517
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W3014078182
- Cited by
- 213
- References
- 8
- FWCI
- 24.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.